New treatment option for advanced urothelial cancer patients shows promise in a phase 2 clinical trial
A new treatment for advanced urothelial cancer was effective with tolerable side effects in an international, multi-center phase 2 clinical trial led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.